메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

SINGAPORE, Dec. 8, 2025 -- TenPay Global, Tencent's cross-border payment platform, and Mastercard Move, Mastercard's money movement business, have announced a collaboration to facilitate fast, secure and transparent digital remittances directly to Weixin Pay, a leading mobile payment service within the Weixin ecosystem in China. Through Mastercard Move, Mastercard's portfolio of money movement capabilities, eligible senders around the world will be able to send salaries and family support directly to Weixin Pay Wallet Balance or linked bank cards in Weixin Pay. According to the
- 황정호 기자
- 2025-12-08 09:00
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year. -- Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meanin
- 김갑성 기자
- 2025-12-08 09:00
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to a situation report by the World Health Organization (WHO), more than 170,000 cases of mpox were confirmed in 141 countries between January 2022 and October 20253. WHO also reported that surveillance d
- 김갑성 기자
- 2025-12-08 09:00
Global Times: Mogao Caves' mural paintings meet modern technology

BEIJING, Dec. 8, 2025 -- The flying Apsaras dance across the heavens; caravan bells echo along ancient routes. Dunhuang, a pivotal hub on the ancient Silk Road, served as a crossroads where diverse civilizations converged, giving birth to the radiant splendor of the Mogao Caves. As a world-renowned treasure house of art and cultural heritage, it integrates architectural excellence, sculptural artistry, mural paintings and Buddhist culture, which embody profound historical depth, rich cultural significance, and breath-taking artistic grandeur. To showcase the contemporary brilliance of
- 김장윤(JASON KIM) 기자
- 2025-12-08 08:48
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology5 achieved PR or better. Six patients (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refra
- 김갑성 기자
- 2025-12-08 08:15
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support. The 1Bio™AI-Acute system use
- 김갑성 기자
- 2025-12-08 08:00
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 -- ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. This surge refl
- 김갑성 기자
- 2025-12-08 08:00
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia. ProstACT Global is the first Phase 3 trial t
- 김갑성 기자
- 2025-12-08 06:08
Blokees、ブラジルのCCXP25に出展：新作「聖闘士星矢」製品の世界初公開

上海、2025年12月8日 -- 12月4日から7日まで、Assembly Character ToysブランドのBlokeesは、ブラジルで開催されたコミックコン・エクスペリエンス（CCXP）に初出展しました。Blokeesは、世界的に著名な「トランスフォーマー」、「ジュラシック・ワールド」、「聖闘士星矢」、「新世紀エヴァンゲリオン」など10を超えるIPを基にした、約60製品を展開する2つの主要カテゴリー「Blokees Model Kits」と「BLOKEES WHEELS」を出展しました。 CCXPでは、ブラジル市場の期待に応える形で、世界初公開となる「Saint Seiya GALAXY VERSION 03 Gold Zodiac ①」が正式に発表されました。この新製品セットには、多彩な表情と精巧なゴールドクロスを備えた9体のキャラクターが含まれています。本作は原作の名場面を鮮やかに再現し、12人の黄金聖闘士をすべて集めたいというファンの共感とコレクション意欲を大いに掻き立てました。なお、聖闘士星矢は2024年にBlokeesよりHERO 10シリーズおよびChampionシリーズとして商品化されています。CCXPでは、BlokeesのSaint Seiya Championシリーズより、3体のグレーモデル、3体の彩色モデル
- 김장윤(JASON KIM) 기자
- 2025-12-08 03:14
陝西省の冬：文化、ウェルネス、再生の聖域

西安市（中国）、2025年12月8日 -- Shaanxi Provincial Department of Culture and Tourismからのニュースリリース：今年の冬、ゆったりとした時間を求める方々にとって、陝西省はとても魅力的な旅先となります。歴史情緒あふれる西安市の温もりから、漢中市の静謐な自然の隠れ家まで、この地は旅人を余裕ある発見の季節へと誘います。近年、より多くの旅行者が寒い季節に訪れることを選んでおり、それは慌ただしい観光ではなく、心の安らぎとリフレッシュを求める旅を楽しむためです。同省は世界中から訪れる旅行者に、より深く記憶に残る体験を提供することに注力し、観光インフラやサービスの充実を着実に進めています。西安市の冬の朝は、ジャイアント・ワイルド・グース・パゴダ（大雁塔）での夜明けとともに始めることができます。澄み渡る空気の中、かつて僧侶Xuanzang氏が経典翻訳を行った古塔は、柔らかな朝日を浴びながら佇み、千年以上にわたって培われてきた静謐な安らぎを感じさせます。この季節の西安市には、凛とした空気と心地よい温もりが共存しています。華清池に立ち上る湯けむりから、市内各所に点在する多様な温泉まで、文化的発見と身体の休息を優しくつなぐ架け橋となります。この雰囲気に、陝西省歴史博物館が所蔵する至宝の数々、唐代
- 김장윤(JASON KIM) 기자
- 2025-12-08 00:22

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2026-01-12_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 12일 18시 00분